Bentley Pharmaceuticals Selects Sedor as President

PharmaManufacturing.com
08/29/2005

Bentley Pharmaceuticals, Inc. (Exeter, N.H.), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, announced August 29 John A. Sedor as its new president. Sedor succeeds James R. Murphy, who will remain chairman and CEO of the company.

Sedor has a 30-year track record as a successful business leader in the pharmaceutical, biotechnology and consumer products industries. Most recently, he was president and CEO of Sandoz, Inc. (a division of Novartis A.G.), and he held similar positions at Verion, Inc., and Centeon, LLC. Other industry experience includes positions at Rhone-Poulenc, Rorer, Revlon Health Care Group, Armour Pharmaceutical Company, and Parke-Davis. Sedor is a past Chairman of the International Plasma Products Industry Association, and a former board member of Quantum Homecare, Applied Immune Sciences and the National Pharmaceutical Council.

"We are very fortunate to find an accomplished individual with John's experience and talent to join our team," said Murphy. "He combines two very distinct sets of skills, those of a pharmaceutical veteran and those of a strategic leader. He has built successful companies utilizing this expertise for thirty years. As Bentley Pharmaceuticals grows in Europe and expands into the United States, we need the abilities and background he brings to the table. We expect him to drive the implementation of our strategic plan for growing Bentley's world-wide business."

Sedor commented, "I am very excited about joining Bentley at this stage of the Company's development. With the business moving beyond its Spanish base in Europe, and with its expansion into the U.S. market, there is a need for greater focus on the strategic direction of the Company. I firmly believe that my experience and training, combined with Bentley's exciting drug delivery technology, will enable Bentley to fulfill its potential. I look forward to working side-by-side with Jim and the rest of the Bentley management team to advance the Company's technology and manage its growth."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.